Prolactin receptor signaling induces acquisition of chemoresistance and reduces clonogenicity in acute myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Prolactin receptor signaling induces acquisition of chemoresistance and reduces clonogenicity in acute myeloid leukemia ; volume:23 ; number:1 ; day:19 ; month:5 ; year:2023 ; pages:1-18 ; date:12.2023
Cancer cell international ; 23, Heft 1 (19.5.2023), 1-18, 12.2023
- Urheber
-
Cuesta-Casanovas, Laia
Delgado-Martínez, Jennifer
Cornet-Masana, Josep M.
Carbó, José M.
Banús-Mulet, Antònia
Guijarro, Francesca
Esteve, Jordi
Risueño, Ruth M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-023-02944-4
- URN
-
urn:nbn:de:101:1-2023090911514832881414
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cuesta-Casanovas, Laia
- Delgado-Martínez, Jennifer
- Cornet-Masana, Josep M.
- Carbó, José M.
- Banús-Mulet, Antònia
- Guijarro, Francesca
- Esteve, Jordi
- Risueño, Ruth M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prolactin Reduces Hippocampal Parvalbumin and GABA A Receptor Expression in Female Mice
The microRNA signature of chemoresistance in acute myeloid leukemia
NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints
Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity
Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
Sunitinib effectively reduces clonogenic acute myeloid leukemia cells in vitro
Prolactin Heterogeneity: A Limitation on the Evaluation of Results from Prolactin Assays due to Differences in Immunoassays and the Different Bioactivities of Prolactin Forms
Grass Carp Prolactin Gene: Structural Characterization and Signal Transduction for PACAP-induced Prolactin Promoter Activity
Prolactin Reduces Hippocampal Parvalbumin and GABA A Receptor Expression in Female Mice
The microRNA signature of chemoresistance in acute myeloid leukemia
NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints
Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity
Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
Sunitinib effectively reduces clonogenic acute myeloid leukemia cells in vitro
Prolactin Heterogeneity: A Limitation on the Evaluation of Results from Prolactin Assays due to Differences in Immunoassays and the Different Bioactivities of Prolactin Forms
Grass Carp Prolactin Gene: Structural Characterization and Signal Transduction for PACAP-induced Prolactin Promoter Activity
Prolactin Reduces Hippocampal Parvalbumin and GABA A Receptor Expression in Female Mice
The microRNA signature of chemoresistance in acute myeloid leukemia
NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints
Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity
Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
Sunitinib effectively reduces clonogenic acute myeloid leukemia cells in vitro
Prolactin Heterogeneity: A Limitation on the Evaluation of Results from Prolactin Assays due to Differences in Immunoassays and the Different Bioactivities of Prolactin Forms